ALSO NOTED: Intradigm completes $16M Series A financing; Prana to raise $6M to fund trial; and much more...

> Intradigm Corporation has completed a $16 million Series A financing, and has also relocated company headquarters to Palo Alto, CA from Rockville, MD. Intradigm is developing RNAi technology--a hot field which has seen a number of deals as of late. Release

> Australia-based Prana Biotechnology announced that it will raise $6 million from investors to fund a trial of PBT2 in patients with Alzheimer's disease. Release

> Chutes & Ladders: SciClone Pharmaceuticals COO Dr. Alfred Rudolph has resigned. CEO Friedhelm Blobel will temporarily take over Rudolph's duties while the company searches for his successor. Report

> Dyax has completed the double-blind portion of its pivotal Phase III clinical trial for DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). The FDA has also broadened the drug's Fast Track designation to include all types of HAE attacks. Release

And Finally... Decreasing lab space--and increasing rent--is pushing biotech out of Cambridge, MA and into the suburbs. Article